Re: Moviprep adverse reactions

[Guest guest]

yes, these! i am looking for moviprep product insert to see if it's on there..if it is, why not on miralax?

WARNINGS AND PRECAUTIONS

Risk of fluid and electrolyte abnormalities, arrhythmias, seizures and renal impairment – encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use (5.1, 5.2, 5.3) Patients with impaired renal function or patients taking concomitant medications that affect renal function – use caution, ensure adequate hydration and consider testing (5.4) Suspected GI obstruction or perforation – rule out the diagnosis before administration (5.6) Patients at risk for aspiration —observe during administration (5.7) Glucose-6-phosphate dehydrogenase deficiency (G-6-PD) – use with caution (5.8) Contains phenylalanine (233 mg per treatment) (5.9)

ADVERSE REACTIONS

Most common adverse reactions for split dosing (incidence ≥ 5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain (6). The most common adverse reactions for evening only dosing (incidence ≥ 5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness (6).

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals, Inc. at 1- or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Oral medications may not be absorbed when administered while taking MoviPrep. (7)http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=47279

[Guest guest]

my point exactly! Grin...........To: miralax Sent: Thu, March 29, 2012 9:25:52 AMSubject: Re: Moviprep adverse reactions

yes, these! i am looking for moviprep product insert to see if it's on there..if it is, why not on miralax?

WARNINGS AND PRECAUTIONS

Risk of fluid and electrolyte abnormalities, arrhythmias, seizures and renal impairment – encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use (5.1, 5.2, 5.3) Patients with impaired renal function or patients taking concomitant medications that affect renal function – use caution, ensure adequate hydration and consider testing (5.4) Suspected GI obstruction or perforation – rule out the diagnosis before administration (5.6) Patients at risk for aspiration —observe during administration (5.7) Glucose-6-phosphate dehydrogenase deficiency (G-6-PD) – use with caution (5.8) Contains phenylalanine (233 mg per treatment) (5.9)

ADVERSE REACTIONS

Most common adverse reactions for split dosing (incidence ≥ 5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain (6). The most common adverse reactions for evening only dosing (incidence ≥ 5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness (6).

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals, Inc. at 1- or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Oral medications may not be absorbed when administered while taking MoviPrep. (7)http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=47279